// App-Quantinova.ai

THU0314 (2018) : Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials

Researchers

Presenter

  • L.C. Coates

Principal Investigators

  • M.E. Husni

  • E. Lespessailles

  • L. Kerr

  • G. Gallo

Medical Centers

  • Univ of Leeds, School of Medicine, Leeds, United Kingdom

  • Cleveland Clinic, Cleveland, OH

  • Orleans Hospital, Orleans, France

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Interleukin

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT01695239

  • NCT02349295

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved